ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS

Glioblastoma (GBM) remains the deadliest of all primary brain tumors with very few effective treatment options. Recently, we reported that high AXL expression is correlated with poor prognosis in GBM patients and demonstrated the therapeutic benefits of targeting AXL, a member of TAM receptor tyrosi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Ghosh, Sadashib, Sadahiro, Hirokazu, Kang, Kyung-Don, Gibson, Justin T, Minata, Mutsuko, Yu, Hai, Shi, Junfeng, Chhipa, Rishi, Chen, Zhihong, Lu, Songjian, Simoni, Yannick, Furuta, Takuya, Sabit, Hemragul, Zhang, Suojun, Bastola, Soniya, Yamaguchi, Shinobu, Alsheikh, Heba Allah, Komarova, Svetlana, Wang, Jun, Kim, Sung-Hak, Hambardzumyan, Dolores, Lu, Xinghua, Newell, Evan W, Dasgupta, Biplab, Nakada, Mitsutoshi, Lee, L James, Nabors, L Burt, A. Norian, Lyse, Nakano, Ichiro
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2018
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216174/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.054
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge